Journal article

Perampanel for the treatment of patients with myoclonic seizures in clinical practice: Evidence from the PERMIT study

W D'Souza, T Alsaadi, J Montoya, M Carreño, C Di Bonaventura, R Mohanraj, T Yamamoto, R McMurray, O Shastri, V Villanueva

Seizure | Published : 2022

Abstract

Purpose: To investigate the effectiveness, safety and tolerability of perampanel (PER) in treating myoclonic seizures in clinical practice, using data from the PERaMpanel pooled analysIs of effecTiveness and tolerability (PERMIT) study. Methods: PERMIT was a pooled analysis of 44 real-world studies from 17 countries, in which patients with focal and generalised epilepsy were treated with PER. This post-hoc analysis included patients with myoclonic seizures at baseline. Retention and effectiveness were assessed after 3, 6, and 12 months; effectiveness was additionally assessed at the last visit (last observation carried forward). Effectiveness assessments included responder rate (≥50% seizure..

View full abstract

University of Melbourne Researchers